Castle Rock Wealth Management LLC Buys New Stake in Pfizer Inc. $PFE

Key Points

• Castle Rock Wealth Management LLC has acquired a new stake in Pfizer Inc. by purchasing 13,220 shares valued at approximately $323,000 in the second quarter.
• Pfizer reported earnings of $0.78 per share in its last quarterly results, exceeding estimates and achieving a 10.3% revenue increase year-over-year.
• Analysts have a generally cautious outlook on Pfizer, with most ratings categorized as "Hold", and target prices ranging from $25 to $30.

Castle Rock Wealth Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,220 shares of the biopharmaceutical company's stock, valued at approximately $323,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the first quarter valued at $27,000. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter valued at $28,000. Horizon Financial Services LLC bought a new stake in Pfizer in the first quarter worth $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the first quarter worth $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $25.67 on Thursday. The company has a 50 day moving average price of $24.79 and a 200-day moving average price of $24.15. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market capitalization of $145.95 billion, a PE ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The company's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Finally, UBS Group reiterated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.